BIOCELTIX S.A. ZY -10 (F:XI3) — Market Cap & Net Worth
Market Cap & Net Worth: BIOCELTIX S.A. ZY -10 (XI3)
BIOCELTIX S.A. ZY -10 (F:XI3) has a market capitalization of $109.87 Million (€93.97 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #18822 globally and #1738 in its home market, demonstrating a 1.87% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BIOCELTIX S.A. ZY -10's stock price €17.46 by its total outstanding shares 5382253 (5.38 Million).
BIOCELTIX S.A. ZY -10 Market Cap History: 2021 to 2026
BIOCELTIX S.A. ZY -10's market capitalization history from 2021 to 2026. Data shows growth from $69.22 Million to $109.87 Million (21.02% CAGR).
BIOCELTIX S.A. ZY -10 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BIOCELTIX S.A. ZY -10's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of XI3 by Market Capitalization
Companies near BIOCELTIX S.A. ZY -10 in the global market cap rankings as of May 5, 2026.
Key companies related to BIOCELTIX S.A. ZY -10 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
BIOCELTIX S.A. ZY -10 Historical Marketcap From 2021 to 2026
Between 2021 and today, BIOCELTIX S.A. ZY -10's market cap moved from $69.22 Million to $ 109.87 Million, with a yearly change of 21.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €109.87 Million | -28.30% |
| 2025 | €153.22 Million | +36.49% |
| 2024 | €112.26 Million | -8.51% |
| 2023 | €122.70 Million | +141.34% |
| 2022 | €50.84 Million | -26.55% |
| 2021 | €69.22 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of BIOCELTIX S.A. ZY -10 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $109.87 Million USD |
| MoneyControl | $109.87 Million USD |
| MarketWatch | $109.87 Million USD |
| marketcap.company | $109.87 Million USD |
| Reuters | $109.87 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BIOCELTIX S.A. ZY -10
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic… Read more